News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Body Recommends Eli Lilly and Company (LLY), Amylin Pharmaceuticals, Inc. (AMLN) Diabetes Drug Bydureon



1/13/2012 6:35:45 AM

The U.K.'s health-care cost-effectiveness body Friday confirmed initial guidance recommending Eli Lilly & Co. (LLY) and Amylin Pharmaceuticals Inc.'s (AMLN) Type 2 diabetes drug Bydureon for use in the U.K.'s publicly funded National Health Service. In final guidance, the National Institute for Health and Clinical Excellence, or NICE, said the injectable medicine, known generically as exenatide, could be given in combination with certain other drugs in obese patients with a body mass index above 35, or those for whom insulin injections wouldn't be suitable.



comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES